Posted by Michael Wonder on 20 Jun 2022
Zeposia is included in the high-cost protection with limitation
17 June 2022 - Zeposia (ozanimod) is included in the high-cost protection with limited subsidy from 17 June 2022.
Zeposia is used to treat adult patients with moderate to severe active ulcerative colitis who have had insufficient response to, no longer respond to, or have been intolerant to either conventional treatment or a biological drug.
The restriction means that Zeposia is only subsidised for patients with ulcerative colitis when tofacitinib citrate is not appropriate.
